Recommendations for the treatment of nosocomial infections caused by Gram-positive microorganisms;Recomendaciones para el tratamiento de las infecciones nosocomiales producidas por microorganismos grampositivos

Revista Espanola de Quimioterapia

Volumn 17, Issue 3, 2004, Pages 271-288

  Azanza, J R ^a   Barberan J ^b   Garcia Rodriguez J A ^a   Llinares, P ^a   Mensa, J ^a   Picazo, J ^a   Prieto, J ^a   Torre Cisneros, J ^a  

^a Soc Espanola de Quimioterapia ^*

^b Soc Espanola de Med Interna (SEMI)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; EVERNINOMICIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METICILLIN; ORITAVANCIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANEMIA; BACTERIAL ENDOCARDITIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CONFERENCE PAPER; DIARRHEA; GRAM POSITIVE BACTERIUM; HEADACHE; HOSPITAL INFECTION; HUMAN; LEUKOPENIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OSTEOMYELITIS; PANCYTOPENIA; PHLEBITIS; RASH; THROMBOCYTOPENIA; VESTIBULAR DISORDER;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CENTRAL NERVOUS SYSTEM INFECTIONS; CLINICAL PROTOCOLS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDOCARDITIS, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PNEUMONIA, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 9644300870     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (170)

1. González-Romo, F., Rubio, M., Betriu, C., Picazo, J.J. y Grupo IGP. Prevalencia y tratamiento de las infecciones par gramposistivos en los servicios de medicina interna de hospitales españoles: Estudio IGP. Rev Esp Quimioterap 2003; 16: 428-435.
2. Betriu, C., Palau, L., Gómez, M., Sánchez, A., Romero, J., Picazo, J.J. Bacteriemias en un hospital universitario: Estudio de los agentes etiológicos y de sus patrones de sensibilidad. Rev Clin Esp 1999; 199: 503-510.
3. Ezpeleta, C. Bacteriemias intrahospitalarias. Rev Clin Esp 1997; 197 (monográfico 5): 15-20.
4. Edmond, M. B., Wallace, S.E., McClish, D.K., Pfaller, M.A., Jones, R.N., Wenzel, R.P. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999; 29: 239-244.
5. García-Leoni, M.E., Moreno, S., Rodeno, P., Cercenado, E., Vicente, T., Bouza, E. Pneumococcal pneumonia in adult hospitalized patients infected with the human immunodeficiency virus. Arch Intern Med 1992; 152: 1808-1812.
6. Guerrero, A. Estudio etiológico de las osteomielitis bacterianas. Enferm Infecc Microbiol Clin 1987; 5: 517-520.
7. Fluit, A.C., Schmitz, F.J., Verhoef, J. Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur J Clin Microbiol Infect Dis 2001; 20: 188-191.
8. Vaqué, J. y Grupo de Trabajo EPINE. Evolución de la prevalencia de las infecciones nosocomiales en los hospitales españoles (Proyecto EPINE 1990-1999). Sociedad Española de Medicina Preventiva, Salud Pública e Higiene, Madrid 2001.
9. Diekema, D.J., Pfaller, M.A., Schmitz, F.J., Smayevsky, J., Bell, J., Jones, R.N., Beach, M., and the SENTRY Participants Group. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32: S114-S132.
10. Jones, R.N., Marshall, S.A., Pfaller, M.A. y cols. Nosocomial enterococcal blood stream infections in the SCOPE Program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. Diagn Microbiol Infect Dis 1997; 29: 95-102.
11. Villablanca, J.G., Steiner, M., Kersey, J. y cols. The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant 1990; 5: 387-393.
12. Betriu, C., Romero, J. Clostridium difficile. Med Clin 1997; 108: 146-155.
13. Betriu, C., Ali Sánchez, B., Picazo, J.J., Grupo G+R. Estudio epidemiológico de la infección por grampositivos resistentes (estudio G + R). Enferm Infecc Microbiol Clin 2003; 21: 7-11.
14. Coello, R., Glynn, J.R., Gaspar, C., Picazo, J.J., Fereres, J. Risk factors for developing clinical infection with methicillin-resistant Staphylococcus aureus (MRSA) amongst hospital patients initially only colonized with MRSA. J Hosp Infect 1997; 37: 39-46.
15. Cercenado, E., Sánchez-Carrillo, C., Alcalá, L., Bouza, E. Situación actual de la resistencia de Staphylococcus en España. Cuarto estudio nacional (1996). Grupo de Trabajo para et Estudio de Estafilococos. Rev Clin Esp 1997; 197 (Suppl. 2): 12-18.
16. Picazo, J.J., Betriu, C., Rodríguez-Avial, I., Azahares, E., Ali Sánchez, B. y Grupo VIRA. Vigilancia de resistencias a los antimicrobianos: Estudio VIRA. Enferm Infecc Microbiol Clin 2002; 20: 503-510.
17. Stefani, S., Varaldo P.E. Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect 2003; 9: 1179-1186.
18. Boisson, K., Thouverez, M., Talon, D., Bertrand, X. Characterisation of coagulase-negative staphylococci isolated from blood infections: Incidence, susceptibility to glycopeptides, and molecular epidemiology. Eur J Clin Microbiol Infect Dis 2002; 21: 660-665.
19. Cercenado, E., García-Leoni, M.E., Díaz, M.D. y cols. Emergence of teicoplanin-resistant coagulase-negative staphylococci. J Clin Microbiol 1996; 34: 1765-1768.
20. Del'Alamo, L., Cereda, R.F., Tosin, I., Miranda, E.A., Sader, H.S. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides. Diagn Microbiol Infect Dis 1999; 34: 185-191.
21. Sloos, J. H., van de Klundert, J.A., Dijkshoorn, L., van Boven, C.P. Changing susceptibilities of coagulase-negative staphylococci to teicoplanin in a teaching hospital. J Antimicrob Chemother 1998; 42: 787-791.
22. Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T., Tenover, R.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
23. Smith, T.L., Pearson, M.L., Wilcox, K.R. y cols. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340: 493-501.
24. Tenover, F.C., Lancaster, M.V., Hill, B.C. y cols. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020-1027.
25. Sieradzki, K., Roberts, R.B., Haber, S.W., Tomasz, A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340: 517-523.
26. Ploy, M.C., Grelaud, C., Martin, C., de Lumley, L., Denis, F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351: 1212.
27. Oliveira, G.A., Dell-Aquila, A.M., Masiero, R.L. y cols. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect Control Hosp Epidemiol 2001; 22: 443-448.
28. Liu, C., Chambers, H.F. Staphylococcus aureus with heterogeneous resistance to vancomycin: Epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47: 3040-3045.
29. Chang, S., Sievert, D.M., Hageman, J.C. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-1347.
30. Centers for Disease Control and Prevention. Vancomycin-resistant Staphyloccocus aureus-Pennsylvania. MMWR 2002; 51: 626-635.
31. Bozdogan, B., Esel, D., Whitener, C., Browne, F.A., Appelbaum, P.C. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003; 52: 864-868.
32. Fitch, L., Johnson, A.P. Reduced susceptibility to teicoplanin in a methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother 1998; 41: 578.
33. Hassan, I. A., Chadwick, P.R., Johnson, A.P. Clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin in Northwest England. J Antimicrob Chemother 2001; 48: 454-455.
34. Cepeda, J., Hayman, S., Whitehouse, T. y cols. Teicoplanin resistance in methicillin-resistant Staphylococcus aureus in an intensive care unit. J Antimicrob Chemother 2003; 52: 533-534.
35. Cisterna, R., Ibarra, K., Morla, A. Estudio multicéntrico de resistencias en enterococos. Papel de la teicoplanina. Grupo Español de Estudio y Vigilancia de Resistencias. Rev Esp Quimioterap 1999; 12: 237-243.
36. Liñares, J., Tubau, F., Domínguez, M. Antibiotic resistance in Streptococcus pneumoniae in Spain. An overwiew of the 1990s. Mary Ann Liebert, Inc., New York 2000.
37. Navarro, C., Egido, P., Aspiroz, C. y cols. Resistencia a penicilina y otros antimicrobianos en 301 aislamientos clínicos de Streptococcus pneumoniae. Enferm Infecc Microbiol Clin 2000; 18: 314-318.
38. Betriu, C., Casado, M.C., Gómez, M., Sánchez, A., Palau, M.L., Picazo, J.J. Incidence of erythromycin resistance in Streptococcus pyogenes: A 10-year study. Diagn Microbiol Infect Dis 1999; 33: 255-260.
39. Betriu, C., Culebras, E., Gómez, M. Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae. Antimicrob Agents Chemother 2003; 47: 1112-1114.
40. Rodríguez-Avial, I., Rodríguez-Avial, C., Culebras, E., Picazo, J.J. Distribution of tetracycline resistance genes tet(M), tet(O), tet(L) and tet(K) in blood isolates of viridans group streptococci harbouring erm(B) and mef(A) genes. Susceptibility to quinupristin/dalfopristin and linezolid. Int J Antimicrob Agents 2003; 21: 536-541.
41. Kennedy, H.F., Gemmell, C.G., Bagg, J., Gibson, B.E., Michie, J.R. Antimicrobial susceptibility of blood culture isolates of viridans streptococci: Relationship to a change in empirical antibiotic therapy in febrile neutropenia. J Antimicrob Chemother 2001; 47: 693-696.
42. Diekema, D.J., Beach, M.L., Pfaller, M.A., Jones, R.N. Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. Clin Microbiol Infect 2001; 7: 152-157.
43. Zyvoxid™ (linezolid injection, linezolid tablets, linezolid for oral suspension) [package insert]. Pharmacia Upjohn Co., Kalamazoo, MI, April 2000.
44. Stalker, D.J., Jungbluth, G.L. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-1140.
45. Verbist, L., Tjandramaga, B., Hendrickx, B. y cols. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother 1984; 26: 881-886.
46. Rowland, M. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 1990; 18: 184-209.
47. Boeckh, M., Lode, H., Borner, K., Höffken, G., Wagner, J., Koeppe, P. Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother 1988; 32: 92-95.
48. Moellering, R.C. Pharmacokinetics of vancomycin. J Antimicrob Chemother 1984; 14 (Suppl. D): 43-52.
49. Delmee, M., Melin, P., Peetermans, W., Verbist, L., Verschraegen, G. Treatment of Clostridium difficile colitis. Summary of a round table held in Brussels on March, 3rd, 1994. Acta Clin Belg 1995; 50: 114-116.
50. Matzke, G.R. Vancomycin. En: Evans, W.E., Schentag, J.J., Jusko, W.J. (Eds.). Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring. Applied Therapeutics, Vancouver 1992; 15/1-15/31.
51. Wienkers, L.C., Wynalda, M.A., Feenstra, K.L., Slatter, J.G. In vitro metabolism of lineiolid (PNU-100766): Lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco (CA) 1999; A3.
52. 14C]PNU 100766 to healthy human volunteers. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego (CA) 1998; 17.
53. Hammerness, P., Parada, H., Abrams, A. Linezolid: MAOI activity and potential drug interactions. Psychosomatics 2002; 43: 248-249.
54. Villani, P., Regazzi, M.B., Marubbi, F. y cols. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002; 46: 936-937.
55. Exner, K., Lang, E., Borsche, A., Lemperle, G. Efficacy, tolerability and pharmacokinetics of teicoplanin in patients undergoing breast surgery. Eur J Surg 1992; 567 (Suppl.): 33-38.
56. Kropec, A., Daschner, F.D. Penetration into tissues of various drugs active against Gram-positive bacteria. J Antimicrob Chemother 1991; 27 (Suppl. B): 9-15.
57. Martin, C., Bourget, P., Alaya, M. y cols. Teicoplanin in cardiac surgery: Intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues. Antimicrob Agents Chemother 1997; 41: 1150-1155.
58. de Lalla, F., Novelli, A., Pellizzer, G. y cols. Regional and systemic prophylaxis with teicoplanin in monolateral and bilateral total knee replacement procedures: Study of pharmacokinetics and tissue penetration. Antimicrob Agents Chemother 1993; 37: 2693-2698.
59. Lovering, A.M., Zhang, J., Bannister, G.C. y cols. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50: 73-77.
60. Rana, B., Butcher, I., Grigoris, P., Murnaghan, C., Seaton, R.A., Tobin, C.M. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 2002; 50: 747-750.
61. Kutscha-Lissberg, F., Hebler, U., Muhr, G., Koller, M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003; 47: 3964-3966.
62. Steer, J.A., Papini, R.P., Wilson, A.P. y cols. Pharmacokinetics of a single dose of teicoplanin in burn patients. J Antimicrob Chemother 1996; 37: 545-553.
63. Buniva, G., Del Favero, A., Bernareggi, A., Patoia, L., Palumbo, R. Pharmacokinetics of 14C-teicoplanin in healthy volunteers. J Antimicrob Chemother 1988; 21 (Suppl. A): 23-28.
64. Honeybourne, D., Tobin, C., Jevons, G., Andrews, J., Wise, R. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003; 51: 1431-1434.
65. Conte, J.E., Jr., Golden, J.A., Kipps, J., Zurlinden, E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46: 1475-1480.
66. Nasraway, S.A., Shorr, A.F., Kuter, D.J., O'Grady, N., Le, V.H., Cammarata, S.K. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: Comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 37: 1609-1616.
67. Tarral, E., Jehl, F., Tarral, A. y cols. Pharmacokinetics of teicoplanin in children. J Antimicrob Chemother 1988; 21 (Suppl. A): 47-51.
68. Asbury, W.H., Darsey, E.H., Rose, W.B., Murphy, J.E., Buffington, D.E., Capers, Ch.C. Farmacocinética de la vancomicina en neonatos y lactantes: Una evaluación retrospectiva. Ann Pharmacother (ed. esp.) 1993; 1: 267-273.
69. Terragna, A., Ferrea, G., Loy, A. y cols. Pharmacokinetics of teicoplanin in pediatric patients. Antimicrob Agents Chemother 1988; 32: 1223-1226.
70. Kearns, G.L., Abdel-Rahman, S.M., Blumer, J.L. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000; 19: 1178-1184.
71. Lam, Y.W.F., Kapusnik-Uner, J.E., Sachdeva, M., Hackbarth, C., Gambertoglio, J.G., Sande, M.A. The pharmacokinetics of teicoplanin in varying degrees of renal function. Clin Pharmacother 1990; 47: 655-661.
72. Wilson, P.R. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000; 39: 167-183.
73. Shinabarger, D.L., Marotti, K.R., Murray, R.W. y cols. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997;41:2132-2136.
74. Brier, M.E., Stalker, D.J., Aronoff, G.R. y cols. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47: 2775-2780.
75. DePestel, D.D., Peloquin, C.A., Carver, P.L. Peritoneal dialysis fluid concentrations of linezolid in the treatment of vancomycin-resistant Enterococcus faecium peritonitis. Pharmacotherapy 2003; 23: 1322-13266.
76. Kraft, M.D., Pasko, D.A., DePestel, D.D., Ellis, J.J., Peloquin, C.A., Mueller, B.A. Linezolid clearance during continuous venovenous hemodiafiltration: A case report. Pharmacotherapy 2003; 23: 1071-1075.
77. Wilson, A.PR., Grüneberg, R.N., Neu, H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994; 4 (Suppl. 1): 1-30.
78. Rayner, C.R., Forrest, A., Meagher, A.K., Birmingham, M.C., Schentag, J.J. Clinical pharmacodynamics of linezolid in seriously ill patiens treated in a compassionate programme. Clin Pharmacokinetics 2003; 42: 1411-1423.
79. Rybak, M.J., Lerner, S.A., Levine, O.P. y cols. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother 1991; 35: 696-700.
80. Leader, W.G., Chandler, M.T.H., Castiglia, M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995; 28: 327-342.
81. Zimmermann, A.E., Katona, B.G., Plaisance, K.I. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995; 15: 85-91.
82. Cantú, T.G., Yamanaka-Yuen, N.A., Lietman, P.S. Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533-543.
83. Moellering, R.C., Jr. Monitoring serum vancomycin levels: Climbing the mountain because it is there? Clin Infect Dis 1994: 19: 1180-1181.
84. Humphrey, S.J., Curry, J.T., Turman, C.N., Stryd, R.P. Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid. J Cardiovasc Pharmacol 2001; 37: 548-563.
85. Sahai, J., Healy, O.P., Shelton, M.J.. Miller, S.S., Ruberg, J., Polk, R. Comparison of vancomycin and teicoplanin induced histamine release and red man syndrome. Antimicrob Agents Chemother 1990; 34: 765-769.
86. Rubinstein, E., Isturiz, R., Standiford, H.C. Worldwide assessment of linezolid's clinical safety and tolerabilily: Comparator-controlled phase III studies. Antimicrob Agents Chemother 2003; 47: 1824-1831.
87. Gerson, S.L., Kaplan, S.I., Bruss, J.E. y cols. Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 2002; 46: 2723-2726.
88. Richards, M.J., Edwards, J.R., Culver, D.H. y cols. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000; 21: 510-515.
89. Vincent, J.L., Bihari, D.J., Suter, P.M. y cols. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study: EPIC Internacional Advisory Committee. JAMA 1995; 274: 639-644.
90. Rubinstein, E., Cammarata, S., Oliphant, T. y cols. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-412.
91. Wunderink, R.G., Cammarata, S.K., Olipham, T. y cols. Linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia: Continuation of a randomized, double-blind, multicenter study. Clin Ther 2003; 25: 980-992.
92. Fagon, J., Patrick, H., Haas, D.W. y cols.. Treatment of Gram-positive nosocomial pneumonia: Prospective randomized comparison of quinupristin/ dalfopristin versus vancomycin: Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161: 753-762.
93. Stevens, D.L., Herr, D., Lampiris, H. y cols. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-1490.
94. Wunderink, R.G., Rello, J., Cammarata, S.K. y cols. Linezolid vs vancomycin. Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-1797.
95. Cruciani, M., Gatti, G., Lazzarini, L. y cols. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38: 865-869.
96. Mylonakis, E., Calderwood, S.B. Infective endocarditis in adults. N Engl J Med 2001; 345: 1318-1330.
97. Del Río, A., García de la María, C., Marco, F., Miro, J.M., Grupo Estudio EI. Avances en el tratamiento antimicrobiano de la endocarditis infecciosa en el año 2000. Inf Ter Nac Salud 2000; 24: 109-128.
98. Fowler, V.G., Sanders, L.L., Kuo Kong, L. y cols. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin Infect Dis 1999; 28: 106-114.
99. Chang, F.Y., MacDonald, B.B., Peacock, J.E. y cols. A prospective multicenter study of Staphylococcus aureus bacteremia. Incidence of endocarditis, risk factor for mortality, and clinical impact of methicillin resistance. Medicine 2003; 82: 322-332.
100. Wilson, W.R., Karchmer, A.W., Dajani, A.S. y cols. Antibiotc treatment of adults with infective endocarditis due to Streptococci, Enterococci, Staphylococci and Hacek microorganisms. JAMA 1995; 274: 1706-1713.
101. Gilbert, D.N., Moellering, R.C., Sande, M.A. The Sanford Guide to Antimicrobial Therapy, 33th ed. Antimicrobial Therapy, Vermunt 2003.
102. Le, T., Bayer, A.S. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis 2003; 36: 615-621.
103. Marco, F., Miró, J.M., del Río, A. y cols. Efficacy of fosfomicin (Fox) plus imipenem (Imi) or ceftriaxone (Cro) combination in the treatment of experimental endocarditis (EE) due a to methicillin-resistant Staphylococcus aureus (Sarm). 40th Interscience Conference Antimicrobial Agents and Chemotherapy, Toronto/Ontario/Canada 2000; Abstr. 1009.
104. Anwer, S., Keefer, M.C., Evans, T.G. Quinupristin/dalfopristin for treatment of MRSA endocarditis refractory to conventional therapy. Infect Dis Clin Pract 1998; 7: 414-416.
105. Drew, R.H., Perfect, J.R., Srinath, L. y cols. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin- dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 2000; 46: 775-784.
106. Sgarabotto, D., Cusinato, R., Narme, E. y cols. Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococci infections: Evaluation of 5 cases. Scand J Infect Dis 2002; 34: 122-126.
107. Garrigues, B. Synercid emergency prescription program. The French experience. Presse Med 2002; 23: 297-301.
108. Oramas-Shirey, M.P., Buchanan, L.V., Dileto-Fang, C.L. y cols. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother 2001; 47: 349-352.
109. Dressler, L.D., Birmingham, M.C., Karcher, A.W., Rayner, C.R., Flavin, S.M., Schentag, J.J. Results of treating infective endocarditis with linezolid. 40th Interscience Conference Antimicrobial Agents and Chemotherapy, Toronto/Ontario/Canada 2000; Abstr. 2239.
110. Jacqueline, C., Caillon, J., Le Mabecque, V.L.E., Miegeville, A.F., Bugnon, D., Potel, G. Linezolid (LNZ) combined with imipenem (IMP): In vivo synergy in a methicillin-resistant Staphylococcus aureus (MRSA) rabbit endocarditis model. 43rd Interscience Conference Antimicrobial Agents and Chemotherapy, Chicago (IL) 2003; Abstr. B 1093.
111. Andrade-Baiocchi, S., Tognim, M.C., Baiocchi, O.C., Sader, H.S. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: Case report and strain characterization. Diagn Microbiol Infect Dis 2003; 45: 149-152.
112. Llinares, P., Núñez, M., Cordero, L., Pereira, S., Romero, E., Moure, R. Endocarditis infecciosa nosocomial en pacientes sin prótests cardiaca. Rev Clin Esp 1997; 197: 814-818.
113. Vandenesch, F., Etienne, J., Reverdy, M.E., Eykyn, S.J. Endocarditis due to Staphylococcus lugdunensis: Report of 11 cases and review. Clin Infect Dis 1993; 17: 871-876.
114. Llinares, P., Moure, R., Cerqueiro, J. y cols. Endocarditis por Staphylococcus lugdunensis. Incidencia hospitalaria. Enferm Infecc Microbiol Clin 1998; 16: 233-236.
115. Olaison, L., Schadewitz, K., for the Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis. Enterococcal endocarditis in Sweden, 1995-1999: Can shorter therapy with aminoglycosides be used? Clin Infect Dis 2002; 34: 159-166.
116. Gavaldá, J., Onrubia, P.L., Gómez, M.T. y cols. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. J Antimicrob Chemother 2003; 52: 514-517.
117. Safdar, A., Bryan, C.S., Stinson, S., Saunders, D.E. Prosthetic valve en docarditis due to vancomycin-resistant Enterococcus faeciwn: Treatment with chloramphenicol plus minocycline. Clin Infect Dis 2002; 34: 61-63.
118. Thompson, R.L., Lavin, B., Talbot, G.H. Endocarditis due vancomycin-resistant Enterococcus faecium in an inmunocompromised patient: Cure by administering combination therapy with quinupristin-dalfopristin and high-dose ampicillin. South Med J 2003; 96: 818-820.
119. Matsumura, S., Simor, A.E. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxicicline, and rifampin: A synergistic drug combination. Clin Infect Dis 1998; 27: 1554-1556.
120. Birminghan, M.C., Rayner, C.R., Meagher, A.K. y cols. Linezolid for treatment of multidrug-resistant, Gram-positive infections: Experience from a compasionate-use program. Clin Infect Dis 2003; 36: 159-168.
121. Rao, N., White, G.J. Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. Clin Infect Dis 2002; 35: 902-904.
122. Babcock, H.M., Ritchie, D.J., Christiansen, E. y cols. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001; 32: 1373-1375.
123. Ang, J.Y., Lua, J.L., Turner, D.R., Asmav, B.I. Vancomycin-resistant Enterococcus faecium endocarditis in premature infant successfully treated with linezolid. Pediatr Infect Dis J 2003; 22: 1101-1103.
124. Lefort, A., Saleh, M.A., Garry, L. y cols. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or resistant Enterococcus faecalis. Antimicrob Agents Chemother 2000; 44: 3017-3021.
125. Akins Ronda, L., Rybak, M.J. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45: 454-459.
126. Boucher, H.W., Thauvin, E.C., Loebenderg, D. y cols. In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis. Antimicrob Agents Chemother 2001; 45; 208-211.
127. Souli, M., Thauvin, E.C., Eliopoulos, G.M. In vivo activities of evernimicin (SCH 27899) against vancomycin-susceptible and vancomycin-resistant enterococci in experimental endocarditis. Antimicrob Agents Chemother 2000; 44: 2733-2739.
128. Wicox, M., Nathwani, D., Dryden, M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004; 53: 335-344.
129. Girón-González, J.A., Pérez-Cano, R. Tratamiento de las infecciones por enterococo. Rev Clin Esp 2003; 203: 482-485.
130. Noskin, G.A., Peterson, L.R., Warren, J.R. Enterococcus faecium and Enterococcus faecalis bacteremia: Acquisition and outcome. Clin Infect Dis 1995; 20: 296-301.
131. Montecalvo, M.A., Shay, D.K., Patel, P. y cols. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996; 156: 1458-1462.
132. Murray, B.E. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342: 710-720.
133. Dodge, R.A., Daly, J.S., Davaro, R. y cols. High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multi-resistant enterococci. Clin Infect Dis 1997; 25: 1269-1270.
134. Aslangul, E., Baptista, M., Fantin, B. y cols. Selection of glycopeptide-resistant mutants of VanB type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis. J Infect Dis 1995; 171: 106-112.
135. Eliopoulos, G.M. Quinupristin-dalfopristin and linezolid: Evidence and opinion. Clin Infect Dis 2003; 138: 135-142.
136. Mermel, L.A., Farr, B.M., Sheretz, R.J. y cols. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32: 1249-1272.
137. Karchmer, A.W., Longworth, D.L. Infections of intracardiac devices. Infect Dis Clin North Am 2002; 16: 477-505.
138. Gomis, M., Sánchez, B., Ferrández, A., Barberán, J. Infecciones de la piel y los tejidos blandos. Rev Esp Quimioterap 1998; 11 (Supl. 3): 73-79.
139. Smith, A.J., Daniels, T., Bohnen, J.M. Soft tissue infections and the diabetic foot. Am J Surg 1996; 172 (Suppl. 6A): 7S-12S.
140. Colsky, A.S., Kirsner, R.S., Kerdel, F.A. Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface. Arch Dermatol 1998; 134: 1006-1009.
141. Jones, M.E., Schmitz, F.J., Fluit, A.C., Acar, J., Gupta, R., Verhoef, J., and the SENTRY participants group. Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an international surveillance programme. Eur J Clin Microbiol Infect Dis 1999; 18: 403-408.
142. File, T.M., Tan, J.S. Treatment of skin and soft-tissue infections. Am J Med 1995; 169 (Suppl. 5A): 27S-33S.
143. Bisno, A., Stevens, D. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334: 240-245.
144. Hau, T. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Eur J Clin Microbiol Infect Dis 2002; 21: 491-498.
145. Swartz, M.N. Cellulitis. N Engl J Med 2004; 350: 904-912.
146. Landman, D., Quale, J.M. Management of infections due to resistant enterococci: A review of therapeutic options. J Antimicrob Chemother 1997; 40: 161-170.
147. Deery, H.G. Outpatient parenteral anti-infective therapy for skin and soft-tissue infections. Infect Dis Clin North Am 1998; 12: 935-949.
148. Lew, D.P., Waldvogel, F.A. Osteomyelitis. N Engl J Med 1997; 336: 999-1007.
149. Gentry, L.O. Oral antimicrobial therapy for osteomyelitis. Ann Intern Med 1991; 114: 986-987.
150. Rissing, J.P. Antimicrobial therapy for chronic osteomyelitis in adults: Role of the quinolones. Clin Infect Dis 1997; 25: 1327-1333.
151. Stein, A., Bataille, J.F., Drancourt, M. y cols. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998; 42: 3086-3091.
152. Gomis, M., Barberán, J., López-Arceo, J. y cols. Teicoplanin in the treatment of staphylococcal osteomyelitis. Ann Exp Clin Med 1994; 4: 171-176.
153. Melzer, M., Goldsmith, D., Gransden, W. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. Clin Infect Dis 2000; 31: 208-209.
154. Rayner, C.R., Baddour, L.M., Birmingham, M.C., Norden, C., Meagher, A.K., Schentag, J.J. Linezolid in the treatment of osteomyelitis: Results of compassionate use experience. Infection 2004; 32: 8-14.
155. Tsukayama, D.T., Estrada, R., Gustilo, R.B. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. J Bone Joint Surg Am 1996; 78: 512-523.
156. Gillespie, W.J. Prevention and management of infection after total joint replacement. Clin Infect Dis 1997; 25; 1310-1317.
157. Drancourt, M., Stein, A., Argenson, J.N., Zannier, A., Curvale, G., Raoult, D. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 1993; 37: 1214-1218.
158. Zimmerli, W., Widmer, A.F., Blatter, M., Frei, R., Ochsner, P.E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279: 1537-1541.
159. Sociedad Española de Quimioterapia y Sociedad Española de Cirugía Ortopédica y Traumatología. Diagnóstico, tratamiento y prevention de la infección de prótests articulares. Rev Esp Quimioterap 2003; 16: 467-478.
160. Davey, P.G., Rowley, D.R., Phillips, G.A. Teicoplanin - Home therapy for prosthetic joint infections. Eur J Surg Suppl 1992; 567: 23-25.
161. Bassetti, M., Di Biagio, A., Cenderello, G. y cols. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA). J Infect 2001; 43: 148-1489.
162. Steinmetz, M., Kalfas, I.H., Willis, B. y cols. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid: Case report and review of the literature. Crit Care Med 2001; 29: 2383-2385
163. Shaikh, Z.H., Peloquin, C.A., Ericsson, C.D. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis linezolid: Case report and literature review. Scand J Infect Dis 2001; 33: 375-379.
164. Hachem, R., Afif, C., Gokaslan, Z. y cols. Successful treatment of vancomycin-resistant Enterococcus meningitis. Eur J Clin Microbiol Infect Dis 2001; 20: 432-434
165. Graham, P.L., Ampofo, K., Saiman, L. y cols. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatric Infect Dis J 2002; 21: 798-800.
166. Gill, C.J., Murphy, M.A., Hamer, D.H. y cols. Treatment of Staphylococcus epidermidis ventriculo-peritoneal shunt infection with linezolid. J Infection 2002; 45: 129-132.
167. Moylett, E., Pacheco, S., Brow-Elliott, B. y cols. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis 2003; 36: 313-318.
168. Axelrod, J.L., Klein, R.M., Bergen, R.L., Sheikh, M.Z. Human vitreus levels of selected antistaphylococcal antibiotics. Am J Ophthalmol 1985; 100: 570-575.
169. García, E., Mensa, J., López, Y. y cols. Penetration of
170. Fiscella, R.G., Nguyen. T.K.P., Cwik, M.J. y cols. Aqueous and vitreous penetration of levofloxacin after oral administration. Ophthalmology 1999; 106: 2286-2290.